These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 34175020)

  • 1. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
    Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
    Kihara Y; Chun J
    Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
    Hach T; Shakeri-Nejad K; Bigaud M; Dahlke F; de Micco M; Petricoul O; Graham G; Piani-Meier D; Turrini R; Brinkmann V; Nicoletti F
    J Interferon Cytokine Res; 2023 Jun; 43(6):246-256. PubMed ID: 36454249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment.
    Hu S; Hu Y; Tan Z; Zhou C; Zhang C; Yin S; Chen X; Chen K; Wang L; Chen L
    Eur J Pharmacol; 2024 Jul; 974():176630. PubMed ID: 38692426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from S1P receptor targeting in multiple sclerosis.
    Colombo E; Farina C
    Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
    Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
    Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
    [No Abstract]   [Full Text] [Related]  

  • 19. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
    Healy LM; Antel JP
    Curr Drug Targets; 2016; 17(16):1841-1850. PubMed ID: 26424391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.